Faces of Digital Health  By  cover art

Faces of Digital Health

By: Tjasa Zajc
  • Summary

  • Faces of Digital Health is a podcast about digital health, exploring how different healthcare systems adopt technologies in healthcare. Its aim is to satisfy curiosity about different cultures, identify barriers to success in different countries and finding answers and advice for accelerating the success of digital health entrepreneurs.
    Copyright 2018. All rights reserved.
    Show more Show less
Episodes
  • Switzerland, AI and Liquid Biopsies
    Apr 25 2024
    AI and predictive modeling to understand an individual’s immune system function and predict treatment response are still in very early stages. We dream about precision medicine and getting every answer we can for ourselves when we get sick. However, if we look at genomics, only about 20 percent of human coding genes are well-studied. The remaining 80 percent (about 16,000 genes, along with the proteins they make) are largely a mystery. In this episode, you will hear more about the field of immuno-oncology, understand the correlation between tumor development and immune system response, and trends in cancer detection and prevention, especially liquid biopsies - tests for detecting tumors in blood samples. Speaker: Brian Hashemi - Executive Chairman and CEO of Novigenix - a Swiss-based biotech company using AI and RNA sequence analysis to capture the cancer immunity cycle during the multi-stage disease progression and response to therapy. www.facesofdigitalhealth.com https://fodh.substack.com/ Show notes: [00:02:00] The use of AI and RNA sequence analysis in capturing the cancer immunity cycle and disease progression [00:04:00] Biotech in Switzerland [00:06:00] The impact of Swiss biotech capabilities on global healthcare and the specific advancements made by Swiss companies in the field. [00:08:00] Predictions and hopes for the future of healthcare technology, especially in the realms of cancer detection and treatment. [00:10:00] Challenges and opportunities in biotech, and the role of AI in advancing healthcare. [00:12:00] Challenges in Colorectal Cancer Screening [00:14:00] The Impact of Liquid Biopsy on Clinical Trials and Drug Development [00:16:00] Market Adoption and Patient Accessibility to Liquid Biopsy Tests [00:18:00] The Future of Liquid Biopsy and Precision Medicine [00:20:00] Real-world Application and Impact of Novel Biomarkers [00:22:00] Expanding the Reach of Novel Diagnostics Beyond Switzerland [00:24:00] Partnerships and Collaborations to Accelerate Adoption
    Show more Show less
    37 mins
  • Healthtech in the GCC Countries: Focus on Infrastructure and Export Capabilities
    Apr 9 2024
    The Gulf Cooperation Council (GCC) brings together six Arab countries – Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates When one reads about the GCC countries, there’s nothing but the impression of prosperity: high investments, determination, and enthusiasm in tech-supported healthcare. The spending on healthcare by the GCC governments is on an astronomical rise. From a regionwide US$2.4 billion in 2016, it rose to more than US$30 billion in 2021 and is projected to surpass US$104 billion this year, according to a report from the UAE Ministry of Economy. In this episode, Pilar Fernandez Hermida International Go-to-Market expert with 20+ years of experience launching sales & partner ecosystem strategies, talks about the potential of the Middle East and MENA region for healthtech companies, the culture in the Middle East, how to interpret different style of communication here, what are the common entrepreneurial misconceptions, and where to find opportunities. Pilar says that the entrepreneurial spirit here is 10-times as strong as in the US, and that biotech and drug development are the next thing to watch for in the region. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Show notes: [00:02:00] Pilar Fernandez Hermida, an expert in healthcare market strategies, shares insights from Abu Dhabi. [00:04:00] Analysis of the healthcare infrastructure development in GCC post-pandemic. [00:08:00] The role of expats in the Middle East's healthcare transformation. [00:10:00] Public-private partnerships as key opportunities. [00:12:00] Cultural considerations for startups in the GCC. [00:14:00] Misconceptions about the Middle Eastern healthcare market. [00:18:00] Building long-term relationships in business. [00:20:00] Navigating diverse cultural communication in healthcare. [00:24:00] Comparing the entrepreneurial spirit in the Middle East with the U.S. and Europe. [00:28:00] Strategic advice for healthcare entrepreneurs targeting the GCC. [00:30:00] Importance of understanding regulations and digital maturity in MENA. [00:32:00] Future potential in biotech and digital health in the GCC. [00:36:00] The convergence of digital health and biotech.
    Show more Show less
    38 mins
  • DTx in 2024: Where Are We With Business and Reimbursement Models? (Andy Molnar)
    Apr 2 2024
    In the last few years, we've witnessed a whirlwind of developments in the world of Digital Therapeutics (DTx) - from FDA approvals sparking optimism for the industry, to the establishment of regulatory frameworks in countries like Germany, France, and Belgium. However, in 2023, the industry faced a stark reality check, marked by the fall of some key players and healthcare systems' hesitancy towards embracing and financing these innovations. This turbulence has reshaped strategies and raised critical questions about the future of DTx. 🔍 In this episode learn more about: 📊 The current state of the DTx industry in 2024, 🗣️ Key debates of digital therapies industry players, 🌐 Advocacy efforts pushing the boundaries for global adoption, 🚀 Strategies to accelerate the integration of digital therapies worldwide. Newsletter: fodh.substack.com Website: www.facesofdigitalhealth.com
    Show more Show less
    22 mins

What listeners say about Faces of Digital Health

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.